US4916239A
(en)
*
|
1988-07-19 |
1990-04-10 |
Merck & Co., Inc. |
Process for the lactonization of mevinic acids and analogs thereof
|
GB9007738D0
(en)
*
|
1990-04-05 |
1990-06-06 |
British Bio Technology |
Compounds
|
US5223415A
(en)
*
|
1990-10-15 |
1993-06-29 |
Merck & Co., Inc. |
Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
|
US5250435A
(en)
*
|
1991-06-04 |
1993-10-05 |
Merck & Co., Inc. |
Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
|
AU660132B2
(en)
*
|
1992-12-21 |
1995-06-08 |
Bayer Aktiengesellschaft |
Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
|
CA2150372C
(en)
*
|
1993-01-19 |
2002-08-20 |
Nancy L. Mills |
Stable oral ci-981 formulation and process of preparing same
|
IN186880B
(fi)
*
|
1997-10-28 |
2001-12-01 |
Ranbaxy Lab Ltd |
|
IN186879B
(fi)
*
|
1997-10-28 |
2001-12-01 |
Ranbaxy Lab Ltd |
|
ZA9810764B
(en)
*
|
1998-04-22 |
1999-08-13 |
Ranbaxy Lab Ltd |
An improved process of lactonization in the preparation of statins.
|
CA2240983A1
(en)
|
1998-06-18 |
1999-12-18 |
Yong Tao |
Process to manufacture simvastatin and intermediates
|
JP4440476B2
(ja)
*
|
1998-12-10 |
2010-03-24 |
株式会社カネカ |
シンバスタチンの製造方法
|
SK282679B6
(sk)
*
|
1999-04-16 |
2002-11-06 |
Biotika, A. S. |
Spôsob izolácie lovastatínu z vyfermentovanej pôdy
|
PL346392A1
(en)
*
|
1999-06-29 |
2002-02-11 |
Kaneka Corp |
Process for selective lactonization
|
CA2388182A1
(en)
*
|
1999-10-27 |
2001-05-03 |
Merck & Co., Inc. |
Lactonization process
|
PL357533A1
(en)
|
2000-03-03 |
2004-07-26 |
Plus Chemicals, S.A. |
A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
|
NL1017548C2
(nl)
*
|
2001-03-09 |
2002-09-10 |
Synthon Bv |
Een lactonisatie proces.
|
US6797831B2
(en)
*
|
2001-05-18 |
2004-09-28 |
Aurobindo Pharma Limited |
Process for lactonization to produce simvastatin
|
KR100407758B1
(ko)
|
2001-08-27 |
2003-12-01 |
씨제이 주식회사 |
스타틴의 제조에 있어서 락톤화 방법
|
KR100502834B1
(ko)
*
|
2002-03-25 |
2005-07-20 |
보령제약 주식회사 |
개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
|
EP1496982A4
(en)
*
|
2002-04-16 |
2006-07-19 |
Merck & Co Inc |
SOLID FORMS OF SALTS WITH TYROSINE KINASE EFFECT
|
AR040588A1
(es)
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
WO2004056358A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
CA2515179A1
(en)
|
2003-02-11 |
2004-08-26 |
Ferenc Korodi |
Process for preparing simvastatin having controlled ranges of simvastatin dimer content
|
CN1839114A
(zh)
|
2003-08-21 |
2006-09-27 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
US7829552B2
(en)
|
2003-11-19 |
2010-11-09 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyromimetics
|
AU2004317826A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Lupin Ltd |
An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
|
WO2006027790A1
(en)
*
|
2004-09-08 |
2006-03-16 |
Jubilant Organosys Limited |
An improved process for lactonization in the preparation of statins
|
EP1807070A1
(en)
*
|
2004-09-29 |
2007-07-18 |
Schering Corporation |
Combinations of substituted azetidinones and cb1 antagonists
|
WO2006059346A2
(en)
*
|
2004-12-01 |
2006-06-08 |
Morepen Laboratories Limited |
An improved process for lactonization to produce highly pure statins
|
KR20070085874A
(ko)
|
2004-12-09 |
2007-08-27 |
머크 앤드 캄파니 인코포레이티드 |
에스트로겐 수용체 조절제
|
WO2007046842A2
(en)
|
2005-03-02 |
2007-04-26 |
Merck & Co., Inc. |
Composition for inhibition of cathepsin k
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
EP1741427A1
(en)
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmaceutical composition comprising simvastatin and ezetimibe
|
WO2007020079A2
(en)
*
|
2005-08-17 |
2007-02-22 |
Synthon B.V. |
Orally disintegratable simvastatin tablets
|
TWI387592B
(zh)
*
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
US20070117996A1
(en)
*
|
2005-11-21 |
2007-05-24 |
Srinivasulu Gudipati |
Process for preparing simvastatin
|
BRPI0620386A2
(pt)
*
|
2005-12-21 |
2011-12-20 |
Schering Corp |
composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
|
CA2634940A1
(en)
*
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
JP5328640B2
(ja)
|
2006-04-19 |
2013-10-30 |
ノバルティス アーゲー |
6−o−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにcsf−1rシグナル伝達を阻害する方法
|
MX2009002398A
(es)
*
|
2006-09-05 |
2009-03-16 |
Schering Corp |
Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090048335A1
(en)
*
|
2007-08-17 |
2009-02-19 |
Venkata Naga Mandava |
Process for preparing simvastatin
|
EP2222636B1
(en)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
CN102089016A
(zh)
*
|
2008-02-27 |
2011-06-08 |
托门医学股份公司 |
植入物及其制备方法
|
EP2204170A1
(en)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmaceutical composition comprising ezetimibe and simvastatin
|
EP2216016A1
(en)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Process for the preparation of a pharmaceutical composition comprising ezetimibe
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
CN101704808A
(zh)
|
2009-11-20 |
2010-05-12 |
西南合成制药股份有限公司 |
制备他汀类化合物的内酯化方法
|
CN104098537A
(zh)
*
|
2009-11-20 |
2014-10-15 |
北大医药股份有限公司 |
制备他汀类化合物的内酯化方法
|
EP2368543A1
(en)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2675440B1
(en)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2012145471A1
(en)
|
2011-04-21 |
2012-10-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
CN107028926A
(zh)
|
2011-08-26 |
2017-08-11 |
国立大学法人大阪大学 |
糖尿病性心血管并发症的预防/治疗剂
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2597092A1
(en)
|
2011-11-24 |
2013-05-29 |
Sterling Biotech Limited |
A process for purification of lovastatin
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
PL2925888T3
(pl)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Kompozycje i sposoby do stosowania w leczeniu nowotworów
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3055314B1
(en)
|
2013-10-08 |
2018-09-12 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
US10441567B2
(en)
|
2014-01-17 |
2019-10-15 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|